At Protheragen, with over two decades of expertise in biological sciences, we understand the intricate interplay between genetics and complex metabolic disorders like diabetes and obesity. Our diabetes-obesity next-generation sequencing (NGS) panel test service offers a sophisticated and precise approach to identifying genetic predispositions and underlying causes, empowering researchers with actionable insights. This service is a part of our comprehensive Genetically Induced Obesity Causation Analysis, which also includes a monogenic obesity gene test service and a broader obesity gene panel test service.

Beyond targeted genetic testing, Protheragen provides a holistic, one-stop solution for obesity research, encompassing every stage from target identification to preclinical validation. Our capabilities include:

Precision Insights: Protheragen's Diabetes-Obesity NGS Panel Test Service

Protheragen's diabetes-obesity NGS panel test service offers a comprehensive and precise genetic analysis solution. Our service scope covers a broad spectrum of genes implicated in various forms of diabetes (Type 1, Type 2, MODY, neonatal diabetes) and obesity (monogenic, syndromic, polygenic predisposition). We are equipped to handle diverse sample types and provide customized panel designs to meet specific research needs.

Our test service follows a meticulously designed workflow to ensure accuracy, efficiency, and actionable results. Each step is optimized for high-throughput analysis and robust data interpretation.

Sample Collection and Quality Control

Secure collection of biological samples (e.g., blood, saliva, tissue). Rigorous quality control checks are performed to assess DNA/RNA integrity, concentration, and purity, ensuring optimal input for sequencing.

Targeted Library Preparation

Utilizing advanced molecular biology techniques, specific genomic regions associated with diabetes and obesity are enriched. This involves polymerase chain reaction (PCR)-based amplification or probe-based capture methods to create sequencing libraries focused on relevant genes and variants.

NGS

Prepared libraries are loaded onto state-of-the-art NGS platforms. High-throughput sequencing generates millions of short DNA reads, covering the targeted genes multiple times to ensure deep and accurate variant detection.

Bioinformatics Analysis and Variant Calling

Raw sequencing data undergoes a sophisticated bioinformatics pipeline. This includes quality filtering, read alignment to the human reference genome, and precise variant calling, such as single-nucleotide polymorphisms (SNPs), small insertions and deletions (indels), and copy number variations (CNVs) within the targeted regions.

Data Interpretation and Reporting

Identified genetic variants are meticulously annotated and interpreted in the context of established databases and scientific literature. A comprehensive report is generated, highlighting pathogenic, likely pathogenic, and variants of uncertain significance, along with their potential implications for diabetes and obesity.

Workflow

Applications

• Drug target discovery: Pinpointing novel genes and pathways involved in disease pathogenesis, leading to the identification of new therapeutic targets for anti-obesity and anti-diabetic drugs.
• Biomarker identification: Discovering genetic biomarkers for early disease detection, prognosis, and monitoring treatment response.
• Nutrigenomics and lifestyle Interventions: Understanding how genetic variations influence an individual's response to dietary interventions and exercise, enabling personalized lifestyle recommendations.

Advantages

• Deep scientific expertise: Our team comprises seasoned biologists, geneticists, and bioinformaticians with over 20 years of experience in metabolic disease research. This deep domain knowledge ensures accurate interpretation of complex genetic data.
• State-of-the-art NGS platforms: We utilize the latest sequencing technologies, guaranteeing high coverage, superior accuracy, and rapid turnaround times for your projects.
• Customizable panel design: Unlike off-the-shelf solutions, Protheragen offers flexible panel customization, allowing you to focus on specific genes or pathways most relevant to your research questions, optimizing cost and data utility.

Publication Data

Frequently Asked Questions

1. Can this service help in identifying novel genetic associations?

   Yes, by providing deep coverage of relevant genes and pathways, our service certainly contributes to the discovery of novel genetic associations with diabetes and obesity, especially in larger cohort studies.

2. What types of samples are suitable for the diabetes-obesity NGS panel test?

   We typically work with genomic DNA extracted from blood, saliva, or tissue samples. Our team provides detailed guidelines for optimal sample collection and submission to ensure the best results.

3. How long does it take to receive the results?

   While turnaround times vary depending on the project scope and sample volume, we prioritize efficiency without compromising accuracy. Please contact us for an estimated timeline tailored to your specific needs.

Protheragen is your trusted partner in unraveling the genetic complexities of diabetes and obesity. Our diabetes-obesity NGS panel test service, backed by extensive expertise and a comprehensive suite of research solutions, provides the precision and insights needed to drive significant advancements in metabolic health. Please feel free to contact us to discuss your specific project needs and explore how Protheragen can contribute to your project.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Bardet-Biedl Syndrome Panel Test Service
• Comprehensive Monogenic Obesity Panel Test Service
• Non-Syndromic Monogenic Obesity Panel Test Service